An Off-the-Shelf Cell Therapy to Calm Cytokine Storms

Episode Summary

Executive Summary: Mesoblast CEO Silvio Ittescu explains how allogeneic mesenchymal stromal cells can address severe inflammatory diseases that small molecules and antibodies often cannot. He details the industrialized manufacturing behind RyanCell, its FDA approval for pediatric steroid-refractory acute GVHD, real-world uptake, and the company’s plans to expand into adult GVHD, heart failure, and inflammatory back pain through a second-generation, locally injected product.

Main Topics: Mesenchymal stromal cells and industrialized manufacturing (Priority: 5/5): Ittescu describes how Mesoblast sources rare precursor cells from healthy donor bone marrow, expands them at scale, freezes them in vials, and ensures potency and consistency for off-the-shelf use across many recipients. RyanCell’s FDA approval and pediatric GVHD (Priority: 5/5): The discussion centers on RyanCell as the first FDA-approved mesenchymal stromal cell therapy in the U.S., approved for steroid-refractory acute GVHD in pediatric patients 2 months and older, and its clinical impact in a high-mortality setting. Mechanism of action in hyperinflammation (Priority: 4/5): Ittescu argues MSCs work because they are activated by inflammatory cytokines and then release anti-inflammatory factors, making them suitable for diseases driven by multiple immune pathways rather than a single target. Commercial launch and reimbursement (Priority: 4/5): He outlines early commercialization of RyanCell, including hospital adoption, insurer coverage, Medicaid support, and the company’s estimates of addressable-market penetration and expansion. Pipeline expansion into larger indications (Priority: 4/5): Mesoblast is pursuing additional uses in adult GVHD, severe heart failure, and inflammatory back pain, positioning the platform as both a rare-disease and larger-volume therapeutic approach. Second-generation product strategy (Priority: 3/5): Rexleny Strohcell is presented as a differentiated, tissue-injected product isolated with monoclonal antibodies and intended for local, higher-volume indications requiring higher yield and lower cost of goods. FDA setbacks and lessons learned (Priority: 3/5): Ittescu reflects on the 2020 and 2023 FDA rejections, emphasizing persistence, stronger long-term data, and manufacturing rigor that now inform subsequent product development.

Key Arguments: Severe inflammatory diseases are often driven by multiple immune pathways, so single-target small molecules or antibodies may be insufficient. Mesenchymal stromal cells are uniquely suited to dampen cytokine-driven hyperinflammation because they are activated by inflammatory mediators and then secrete anti-inflammatory factors. RyanCell’s pediatric GVHD data support both short-term response and long-term survival, validating the platform clinically and commercially. Allogeneic MSCs can be manufactured at industrial scale with consistent potency, enabling off-the-shelf use from one donor to many patients. The company believes its cell therapies can compete economically with biologics, with gross margins already comparable to or better than monoclonal antibodies. Mesoblast’s strategy splits into two tracks: RyanCell for rare, severe diseases and a second-generation product for higher-volume, locally injected indications. FDA experience on RyanCell has strengthened Mesoblast’s regulatory and manufacturing approach for future products.

Data Points: FDA approval year: Late 2024 - RyanCell won U.S. approval in the United States Approved indication: Steroid-refractory acute-versus-host disease - Pediatric patients 2 months of age and older Cell dose per vial: 25 million cells - Each RyanCell vial contains 25 million mesenchymal stromal cells Dose per kilogram: 2 million cells/kg - RyanCell dosing described for children Storage temperature: Minus 130 degrees - Frozen vial storage and cold-chain shipping Mortality without cells: 70% to 80% - Severe pediatric GVHD described as having very high mortality without RyanCell Responder rate: 70% - One-month response after multiple infusions in pediatric GVHD Five-year GVHD death rate after treatment: 14% - Long-term follow-up among children treated with RyanCell Adult expanded-access survival: Over 60% - Adults with severe refractory GVHD who otherwise would have about 25% survival Adult baseline survival: 25% - Referenced for severe refractory GVHD without effective treatment Commercial carrier coverage: 95% - Percent of commercial carriers reportedly covering the product fully Market penetration: About 20% - Current penetration of addressable market after launch Target market penetration: About 40% - Company goal for continued adoption Gross margins: 80% to 90% - Current manufacturing economics for the product class Yield improvement: 5- to 10-fold - Expected improvement from proprietary media and bioreactor implementation Heart failure risk reduction: About 80% - Earlier randomized study showed reduction in heart attacks and strokes over three years Mortality reduction in heart failure: 60% - Earlier randomized study on top of maximum standard of care Back pain phase 3 trial size: 400 patients - First confirmatory-style phase 3 trial in inflammatory back pain Pain durability: As long as 3 years - Responders in back pain trial remained improved or in remission Back pain confirmatory trial enrollment: Expected to complete this quarter - Second phase 3 trial underway with 12-month primary endpoint

Pivotal Quotes: "The unique aspects of these cells is that they can be expanded to large numbers. They don't activate the immune system and therefore can be used from one healthy donor to treat thousands of unrelated recipients." — Silvio Ittescu: Explaining why mesenchymal stromal cells are suitable as an off-the-shelf therapy "The mesenchymal stromal cell is uniquely able to be activated by these multiple arms of the immune system and turn them off." — Silvio Ittescu: Describing the mechanism for treating severe inflammatory disease and GVHD "If you have a product that works, you have to stick with it." — Silvio Ittescu: Reflecting on FDA setbacks and the company’s persistence through repeated review cycles

Implications: Mesoblast’s approval validates MSCs as a real therapeutic class and could expand cell therapy beyond oncology. If adult and larger-volume indications succeed, the platform may reshape treatment for severe inflammation, pain, and cardiac disease.